Andrew DeFrancesco - Scythian Biosciences Chairman of the Board, Chief Investment Officer

SOLCF -  USA Stock  

USD 0.61  0.02  3.17%

  Chairman
Mr. Andrew Anthony DeFrancesco was appointed Chairman of the Board, Chief Investment Officer of the Company effective November 1, 2018. . Currently, he serves as Chairman of the Board for Cool Holdings Inc., a position Mr. DeFrancesco has held since December 2016. Cool Holdings is a Nasdaq listed investment company which currently owns 17 officially licensed Apple boutique retail stores in the Dominican Republic, Argentina and Florida with plans to roll out in multiples states and Canada. Additionally, Mr. DeFrancesco was the Chief Investment Officer and Director of the Delavaco Group, a global private equity firm focused on small and midcapital corporations in select sectors since the sale of Delavaco Energy for 102 million in 2009.
Age: 47  Chairman Since 2018      
212-729-9208  https://solglobal.com

Scythian Biosciences Management Efficiency

Scythian Biosciences Corp has return on total asset (ROA) of 33.29 % which means that it generated profit of $33.29 on every $100 spent on asset. This is very large. Similarly, it shows return on equity (ROE) of 60.73 %, meaning that it generated $60.73 on every $100 dollars invested by stockholders. Scythian Biosciences management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 52.85 M in total debt with debt to equity ratio (D/E) of 0.13, which may suggest the company is not taking enough advantage from borrowing. Scythian Biosciences Corp has a current ratio of 2.77, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Scythian Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Scythian Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scythian Biosciences Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scythian to invest in growth at high rates of return. When we think about Scythian Biosciences' use of debt, we should always consider it together with cash and equity.
Is Scythian Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scythian Biosciences. If investors know Scythian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scythian Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Scythian Biosciences Corp is measured differently than its book value, which is the value of Scythian that is recorded on the company's balance sheet. Investors also form their own opinion of Scythian Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Scythian Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scythian Biosciences' market value can be influenced by many factors that don't directly affect Scythian Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scythian Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Scythian Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scythian Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Curtis ArledgeBank Of New
2014
Gerald HassellBank Of New
2017
J HillBlackstone
N/A
Robert KapitoBlackrock
2014
Jeffrey BlidnerBrookfield Asset Management
2020
Charles ScharfBank Of New
2018
Tomilson HillBlackstone
N/A
Laurence FinkBlackrock
1998
Walter ClaytonApollo Asset Management
2021
Brian SheaBank Of New
N/A
James CracchioloAmeriprise Financial Services
2005
Mark McCombeBlackrock
2019
William DaleyBank Of New
2019
Hani KablawiBank Of New
2020
Joseph EchevarriaBank Of New
2020
Thomas GibbonsBank Of New
2020
Stephen SchwarzmanBlackstone
2007
Robin VinceBank Of New
2022
JTomilson HillBlackstone
N/A
Jack CockwellBrookfield Asset Management
2017
Leon BlackApollo Asset Management
N/A
SOL Global Investments Corp. is a principal investment firm with a focus on the biopharmaceutical and cannabis industry in the United States. The company was formerly known as Scythian Biosciences Corp. and changed its name to SOL Global Investments Corp. in October 2018. Scythian Biosciences operates under Asset Management classification in the United States and is traded on OTC Exchange. Scythian Biosciences Corp [SOLCF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Scythian Biosciences Corp Leadership Team

Elected by the shareholders, the Scythian Biosciences' board of directors comprises two types of representatives: Scythian Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scythian. The board's role is to monitor Scythian Biosciences' management team and ensure that shareholders' interests are well served. Scythian Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scythian Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Brady Cobb, CEO, Director
Rob Reid, Director
Peter Liabotis, CFO
Gabriel Meneses, Vice President - Latin America and Caribbean
Christopher Irwin, Corporate Secretary
Renah Persofsky, Director
Michael Barnes, Chief Medical Officer
Roberto Ruiz, Senior Director - Business Development
Andrew DeFrancesco, Chairman of the Board, Chief Investment Officer
Maghsoud Dariani, Chief Scientific Officer

Scythian Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Scythian Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Scythian Biosciences Investors Sentiment

The influence of Scythian Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Scythian. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Scythian Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Scythian Biosciences' short interest history, or implied volatility extrapolated from Scythian Biosciences options trading.

Current Sentiment - SOLCF

Scythian Biosciences Corp Investor Sentiment

Macroaxis portfolio users are evenly split in their outlook on investing in Scythian Biosciences Corp. What is your outlook on investing in Scythian Biosciences Corp? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Currently Active Assets on Macroaxis

Additionally, take a look at World Market Map. Note that the Scythian Biosciences Corp information on this page should be used as a complementary analysis to other Scythian Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Scythian OTC Stock analysis

When running Scythian Biosciences Corp price analysis, check to measure Scythian Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scythian Biosciences is operating at the current time. Most of Scythian Biosciences' value examination focuses on studying past and present price action to predict the probability of Scythian Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Scythian Biosciences' price. Additionally, you may evaluate how the addition of Scythian Biosciences to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Scythian Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scythian Biosciences. If investors know Scythian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scythian Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Scythian Biosciences Corp is measured differently than its book value, which is the value of Scythian that is recorded on the company's balance sheet. Investors also form their own opinion of Scythian Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Scythian Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scythian Biosciences' market value can be influenced by many factors that don't directly affect Scythian Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scythian Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Scythian Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scythian Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.